Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.

Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, Sinharay S, Scott G, Wu T, Federoff HJ, Zaghloul KA, Hallett M, Lonser RR, Bankiewicz KS.

Mov Disord. 2019 May 30. doi: 10.1002/mds.27724. [Epub ahead of print]

PMID:
31145831
2.

Fetal Bovine Serum-Derived Extracellular Vesicles Persist within Vesicle-Depleted Culture Media.

Lehrich BM, Liang Y, Khosravi P, Federoff HJ, Fiandaca MS.

Int J Mol Sci. 2018 Nov 9;19(11). pii: E3538. doi: 10.3390/ijms19113538.

3.

Protect NIH's DNA advisory committee.

Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L.

Science. 2018 Oct 26;362(6413):409-410. doi: 10.1126/science.aav2483. No abstract available.

PMID:
30361364
4.

Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury.

Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, Federoff HJ.

Metabolites. 2018 Sep 7;8(3). pii: E50. doi: 10.3390/metabo8030050.

5.

Plasma microRNA markers of upper limb recovery following human stroke.

Edwardson MA, Zhong X, Fiandaca MS, Federoff HJ, Cheema AK, Dromerick AW.

Sci Rep. 2018 Aug 22;8(1):12558. doi: 10.1038/s41598-018-31020-5.

6.

Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development.

Gross T, Mapstone M, Miramontes R, Padilla R, Cheema AK, Macciardi F, Federoff HJ, Fiandaca MS.

Curr Top Med Chem. 2018;18(11):883-895. doi: 10.2174/1568026618666180711144323. Review.

PMID:
29992885
7.

Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls.

Fiandaca MS, Mapstone M, Mahmoodi A, Gross T, Macciardi F, Cheema AK, Merchant-Borna K, Bazarian J, Federoff HJ.

PLoS One. 2018 Apr 20;13(4):e0195318. doi: 10.1371/journal.pone.0195318. eCollection 2018.

8.

Precision pharmacology for Alzheimer's disease.

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Review.

PMID:
29458203
9.

Systems healthcare: a holistic paradigm for tomorrow.

Fiandaca MS, Mapstone M, Connors E, Jacobson M, Monuki ES, Malik S, Macciardi F, Federoff HJ.

BMC Syst Biol. 2017 Dec 19;11(1):142. doi: 10.1186/s12918-017-0521-2. Review.

10.

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.

Mehta KY, Wu HJ, Menon SS, Fallah Y, Zhong X, Rizk N, Unger K, Mapstone M, Fiandaca MS, Federoff HJ, Cheema AK.

Oncotarget. 2017 Aug 18;8(40):68899-68915. doi: 10.18632/oncotarget.20324. eCollection 2017 Sep 15.

11.

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.

Subramaniam SR, Federoff HJ.

Front Aging Neurosci. 2017 Jun 8;9:176. doi: 10.3389/fnagi.2017.00176. eCollection 2017. Review.

12.

Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.

Su X, Fischer DL, Li X, Bankiewicz K, Sortwell CE, Federoff HJ.

Mol Ther. 2017 Oct 4;25(10):2231-2235. doi: 10.1016/j.ymthe.2017.04.018. Epub 2017 May 15. No abstract available.

13.

Personality and Performance in Specific Neurocognitive Domains Among Older Persons.

Chapman BP, Benedict RH, Lin F, Roy S, Federoff HJ, Mapstone M.

Am J Geriatr Psychiatry. 2017 Aug;25(8):900-908. doi: 10.1016/j.jagp.2017.03.006. Epub 2017 Apr 3.

14.

Biomarker validation: Methods and matrix matter.

Mapstone M, Cheema AK, Zhong X, Fiandaca MS, Federoff HJ.

Alzheimers Dement. 2017 May;13(5):608-609. doi: 10.1016/j.jalz.2016.11.004. Epub 2016 Dec 21. No abstract available.

PMID:
28010950
15.

What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease.

Mapstone M, Lin F, Nalls MA, Cheema AK, Singleton AB, Fiandaca MS, Federoff HJ.

Neurobiol Aging. 2017 Mar;51:148-155. doi: 10.1016/j.neurobiolaging.2016.11.007. Epub 2016 Nov 21.

16.

A genome-wide association study in multiple system atrophy.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.

Neurology. 2016 Oct 11;87(15):1591-1598. Epub 2016 Sep 14.

17.

Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease.

Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT, Gresenz CR, FitzGerald KT, Nalls MA, Singleton AB, Mapstone M, Federoff HJ.

Front Neurol. 2015 Nov 12;6:237. doi: 10.3389/fneur.2015.00237. eCollection 2015.

18.

PGC-1α Promoter Methylation in Parkinson's Disease.

Su X, Chu Y, Kordower JH, Li B, Cao H, Huang L, Nishida M, Song L, Wang D, Federoff HJ.

PLoS One. 2015 Aug 28;10(8):e0134087. doi: 10.1371/journal.pone.0134087. eCollection 2015.

19.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

20.

Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial.

Dromerick AW, Edwardson MA, Edwards DF, Giannetti ML, Barth J, Brady KP, Chan E, Tan MT, Tamboli I, Chia R, Orquiza M, Padilla RM, Cheema AK, Mapstone ME, Fiandaca MS, Federoff HJ, Newport EL.

Front Hum Neurosci. 2015 Apr 29;9:231. doi: 10.3389/fnhum.2015.00231. eCollection 2015.

Supplemental Content

Loading ...
Support Center